MCMedicalCodingSoftware
Free trial
XW04378

XW04378 — Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8

Billable / specific codeICD-10-PCS

CMS abbreviated title: Introduce Tabelecleucel in Central Vein, Perc, New Tech 8

How XW04378 is built

Every ICD-10-PCS code is seven independent character positions. Each one is a separate decision, and the meaning of a character depends on the positions before it.

  1. XSectionNew Technology — What family of procedure this is
  2. WBody systemWhich system it acts on
  3. 0Root operationThe objective — the verb of the procedure
  4. 4Body partThe specific site
  5. 3ApproachHow the site was reached
  6. 7DeviceWhat was left in place, if anything
  7. 8QualifierA further distinction where one applies

Codes near XW04378

In CMS’s own ordering, which groups codes that differ by only the last character or two — usually the approach, device or qualifier.

  • XW0434AIntroduction of Cefepime-taniborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW04357Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW04358Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW0435AIntroduction of Ceftobiprole Medocaril Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW04367Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW04368Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW04372Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2
  • XW04377Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW04378Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW04387Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW04388Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW0438AIntroduction of Obecabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW04396Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW04398Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW0439AIntroduction of Odronextamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW043A7Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043B3Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3
ICD-10-PCSFY2026